Titre : Récepteur de la sérotonine de type 5-HT2A

Récepteur de la sérotonine de type 5-HT2A : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognition
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteur de la sérotonine de type 5-HT2A : Questions médicales les plus fréquentes", "headline": "Récepteur de la sérotonine de type 5-HT2A : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteur de la sérotonine de type 5-HT2A : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-30", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteur de la sérotonine de type 5-HT2A" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteurs de la sérotonine de type 5-HT2", "url": "https://questionsmedicales.fr/mesh/D044348", "about": { "@type": "MedicalCondition", "name": "Récepteurs de la sérotonine de type 5-HT2", "code": { "@type": "MedicalCode", "code": "D044348", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.720.850.200" } } }, "about": { "@type": "MedicalCondition", "name": "Récepteur de la sérotonine de type 5-HT2A", "alternateName": "Receptor, Serotonin, 5-HT2A", "code": { "@type": "MedicalCode", "code": "D044402", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Evgeni Ponimaskin", "url": "https://questionsmedicales.fr/author/Evgeni%20Ponimaskin", "affiliation": { "@type": "Organization", "name": "Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany." } }, { "@type": "Person", "name": "Andre Zeug", "url": "https://questionsmedicales.fr/author/Andre%20Zeug", "affiliation": { "@type": "Organization", "name": "Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany." } }, { "@type": "Person", "name": "Monika Bijata", "url": "https://questionsmedicales.fr/author/Monika%20Bijata", "affiliation": { "@type": "Organization", "name": "Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura 3, 02-093 Warsaw, Poland." } }, { "@type": "Person", "name": "Jakub Wlodarczyk", "url": "https://questionsmedicales.fr/author/Jakub%20Wlodarczyk", "affiliation": { "@type": "Organization", "name": "Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura 3, 02-093 Warsaw, Poland." } }, { "@type": "Person", "name": "Robert B Kargbo", "url": "https://questionsmedicales.fr/author/Robert%20B%20Kargbo", "affiliation": { "@type": "Organization", "name": "Usona Institute, Fitchburg, Wisconsin 53711-5300, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Computerized cognitive and social cognition training in schizophrenia for impulsive aggression.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36424289", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.schres.2022.11.004" } }, { "@type": "ScholarlyArticle", "name": "Treatment preferences among adults with normal cognition and cognitive impairment.", "datePublished": "2022-09-12", "url": "https://questionsmedicales.fr/article/36094330", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jgs.18032" } }, { "@type": "ScholarlyArticle", "name": "Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.", "datePublished": "2023-01-09", "url": "https://questionsmedicales.fr/article/36634906", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.neuroscience.2023.01.004" } }, { "@type": "ScholarlyArticle", "name": "Deep Cognitive Gate: Resembling Human Cognition for Saliency Detection.", "datePublished": "2022-08-04", "url": "https://questionsmedicales.fr/article/33755558", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/TPAMI.2021.3068277" } }, { "@type": "ScholarlyArticle", "name": "Effects of cognitive stimulation program on cognition and mood in older adults, stratified by cognitive levels: A randomized controlled trial.", "datePublished": "2023-03-04", "url": "https://questionsmedicales.fr/article/36921506", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.archger.2023.104984" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs aux neuromédiateurs", "item": "https://questionsmedicales.fr/mesh/D017981" }, { "@type": "ListItem", "position": 7, "name": "Récepteurs sérotoninergiques", "item": "https://questionsmedicales.fr/mesh/D011985" }, { "@type": "ListItem", "position": 8, "name": "Récepteurs de la sérotonine de type 5-HT2", "item": "https://questionsmedicales.fr/mesh/D044348" }, { "@type": "ListItem", "position": 9, "name": "Récepteur de la sérotonine de type 5-HT2A", "item": "https://questionsmedicales.fr/mesh/D044402" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteur de la sérotonine de type 5-HT2A - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteur de la sérotonine de type 5-HT2A", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteur de la sérotonine de type 5-HT2A", "description": "Comment diagnostiquer une dysfonction des récepteurs 5-HT2A ?\nQuels examens sont utilisés pour évaluer les récepteurs 5-HT2A ?\nLes tests sanguins peuvent-ils aider au diagnostic ?\nQuels symptômes indiquent une anomalie des récepteurs 5-HT2A ?\nPeut-on utiliser des biomarqueurs pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteur de la sérotonine de type 5-HT2A", "description": "Quels symptômes sont liés à l'activation des récepteurs 5-HT2A ?\nLes troubles de l'humeur sont-ils associés aux récepteurs 5-HT2A ?\nComment les récepteurs 5-HT2A affectent-ils l'anxiété ?\nLes symptômes psychotiques sont-ils liés aux récepteurs 5-HT2A ?\nQuels autres symptômes peuvent survenir avec une dysfonction 5-HT2A ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteur de la sérotonine de type 5-HT2A", "description": "Peut-on prévenir les troubles liés aux récepteurs 5-HT2A ?\nL'éducation sur la santé mentale aide-t-elle ?\nLes interventions précoces sont-elles bénéfiques ?\nLe soutien social joue-t-il un rôle dans la prévention ?\nLes activités physiques aident-elles à prévenir les troubles ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteur de la sérotonine de type 5-HT2A", "description": "Quels médicaments ciblent les récepteurs 5-HT2A ?\nComment les traitements affectent-ils les récepteurs 5-HT2A ?\nLes thérapies comportementales sont-elles efficaces ?\nY a-t-il des effets secondaires des médicaments ciblant 5-HT2A ?\nLes traitements sont-ils personnalisés pour chaque patient ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteur de la sérotonine de type 5-HT2A", "description": "Quelles complications peuvent survenir avec une dysfonction 5-HT2A ?\nLes complications sont-elles réversibles ?\nLes complications affectent-elles la qualité de vie ?\nLes complications peuvent-elles être prévenues ?\nLes complications psychologiques sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteur de la sérotonine de type 5-HT2A", "description": "Quels sont les facteurs de risque pour les troubles 5-HT2A ?\nL'usage de drogues influence-t-il les récepteurs 5-HT2A ?\nLe sexe influence-t-il les troubles liés aux récepteurs 5-HT2A ?\nLe stress chronique est-il un facteur de risque ?\nLes traumatismes précoces augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D044402?mesh_terms=Cognition&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des récepteurs 5-HT2A ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests neuropsychologiques et l'évaluation des symptômes." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer les récepteurs 5-HT2A ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques d'imagerie cérébrale comme la TEP peuvent être utilisées." } }, { "@type": "Question", "name": "Les tests sanguins peuvent-ils aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, les tests sanguins ne mesurent pas directement l'activité des récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie des récepteurs 5-HT2A ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'anxiété, la dépression ou des troubles psychotiques peuvent indiquer une anomalie." } }, { "@type": "Question", "name": "Peut-on utiliser des biomarqueurs pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour les récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'activation des récepteurs 5-HT2A ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "L'activation peut provoquer des hallucinations, de l'anxiété et des troubles de l'humeur." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils associés aux récepteurs 5-HT2A ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysrégulation des récepteurs 5-HT2A est liée à des troubles de l'humeur." } }, { "@type": "Question", "name": "Comment les récepteurs 5-HT2A affectent-ils l'anxiété ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils modulent la libération de neurotransmetteurs, influençant ainsi l'anxiété." } }, { "@type": "Question", "name": "Les symptômes psychotiques sont-ils liés aux récepteurs 5-HT2A ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une activation excessive des récepteurs 5-HT2A peut contribuer aux symptômes psychotiques." } }, { "@type": "Question", "name": "Quels autres symptômes peuvent survenir avec une dysfonction 5-HT2A ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la perception, des changements d'humeur et des comportements impulsifs peuvent survenir." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés aux récepteurs 5-HT2A ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une gestion du stress et un mode de vie sain." } }, { "@type": "Question", "name": "L'éducation sur la santé mentale aide-t-elle ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation peut réduire le risque de troubles liés aux récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Les interventions précoces sont-elles bénéfiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une intervention précoce peut prévenir l'aggravation des symptômes." } }, { "@type": "Question", "name": "Le soutien social joue-t-il un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un bon soutien social peut aider à prévenir les troubles liés aux récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Les activités physiques aident-elles à prévenir les troubles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé mentale et réduire les symptômes." } }, { "@type": "Question", "name": "Quels médicaments ciblent les récepteurs 5-HT2A ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antipsychotiques atypiques et certains antidépresseurs ciblent ces récepteurs." } }, { "@type": "Question", "name": "Comment les traitements affectent-ils les récepteurs 5-HT2A ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils modulent l'activité des récepteurs, améliorant ainsi les symptômes psychiatriques." } }, { "@type": "Question", "name": "Les thérapies comportementales sont-elles efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent aider à gérer les symptômes liés à la dysfonction des récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des médicaments ciblant 5-HT2A ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme la sédation ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés pour chaque patient ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des symptômes et de la réponse du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction 5-HT2A ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des troubles psychotiques ou des crises d'anxiété peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une gestion proactive des symptômes peut aider à prévenir certaines complications." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications psychologiques sont courantes chez les patients avec dysfonction 5-HT2A." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles 5-HT2A ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux de troubles mentaux et le stress sont des facteurs de risque." } }, { "@type": "Question", "name": "L'usage de drogues influence-t-il les récepteurs 5-HT2A ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines drogues peuvent altérer l'activité des récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Le sexe influence-t-il les troubles liés aux récepteurs 5-HT2A ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le sexe peut influencer la prévalence des troubles." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter le risque de dysfonction des récepteurs 5-HT2A." } }, { "@type": "Question", "name": "Les traumatismes précoces augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traumatismes précoces peuvent prédisposer à des troubles liés aux récepteurs 5-HT2A." } } ] } ] }

Sources (10000 au total)

Computerized cognitive and social cognition training in schizophrenia for impulsive aggression.

Schizophrenia is associated with an elevated risk for impulsive aggression for which there are few psychosocial treatment options. Neurocognitive and social cognitive deficits have been associated wit... The two-center study randomized 130 participants to receive 36 sessions of either a combination of cognitive remediation and social cognition treatment or cognitive remediation plus a computer-based c... Study participants were mostly male (84.5 %), had a mean age 34.9 years, and 11.5 years of education. Both Cognitive Remediation Training (CRT) plus Social Cognition Training (SCT) and CRT plus contro... CRT proved to be an effective non-pharmacological treatment in reducing impulsive aggression in schizophrenia inpatient participants with a history of aggressive episodes. The addition of social cogni...

Treatment preferences among adults with normal cognition and cognitive impairment.

Although patient participation in treatment decisions is important for preference-concordant care delivery, it is largely unknown how cognitive impairment influences treatment preferences. We investig... Data from the 2018 Health and Retirement Study were used. The sample included 1291 self-respondents (201 respondents with cognitive impairment, and 1090 with normal cognition). We examined treatment p... Respondents with cognitive impairment were more likely to report that they were unsure about treatment options across both clinical scenarios compared to those with normal cognition. For the limited t... Compared to those with normal cognition, cognitive impairment was associated with greater uncertainty about treatment preferences and higher rates of aggressive care preferences among those who specif...

Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.

Subjective cognitive decline (SCD) and objective subtle cognitive difficulties (Obj-SCD) are considered the initial stages of aberrant cognition prior to mild cognitive impairment (MCI) due to Alzheim...

Effects of cognitive stimulation program on cognition and mood in older adults, stratified by cognitive levels: A randomized controlled trial.

Cognitive stimulation (CS) is defined as activities that involve cognitive processing, usually conducted in a social context and often in a group. This study aims to evaluate the effects of a personal... The randomized controlled single-blind trial involving 337 participants (235 women and 102 men) ≥ 65 years of age in a Primary Care centre classified participants into 4 groups: 101 for the no deterio... The intervention showed a tendency of improvement on global cognition and different cognitive functions for groups with no deterioration or level deterioration. The group with moderate deterioration i... The findings demonstrated benefits in global cognition, different cognitive functions, semantic fluency, IADLs and anxiety. The most benefits are given in the intermediate groups, SCI, and LD. Moreove...

The Effect of Hearing Loss on Cognitive Function in Subjective Cognitive Decline.

Subjective cognitive decline (SCD) is a self-reported cognitive decline without objective cognitive impairment. The relationship between audiometric hearing loss (HL) and cognitive function has not be... This is a cross-sectional study that used the baseline data of a multicenter cohort study that monitors clinical progression from SCD to dementia. Individuals aged ≥60 years who reported cognitive dec... Of a total of 120 participants, one hundred and two had NH (n = 57) or bilateral HL (n = 45). There were no group differences in the demographic and clinical data except the age. The biomarkers, globa... In SCD, HL exerted an adverse effect on cognitive function, primarily frontal executive function tested in the Stroop task. HL was also related to gray matter volume reductions in brain subregions, al...

Physical and cognitive function to explain the quality of life among older adults with cognitive impairment: exploring cognitive function as a mediator.

Physical and cognitive function are both indicators of aging, characterized by a loss of adaptive response to life challenges and functional limitations, subsequently affecting their quality of life. ... The study participants were 79 older adults recruited from community centers in four urban districts of Korea. All participants completed a self-reported questionnaire for demographic characteristics ... The mean age of participants was 77.46 years old with an elementary or lower education level (53.2%). The mean score of cognitive function was 16.39 (SD = 6.5). Physical function (grip strength, balan... In conclusion, physical and cognitive function were significant predictors of QOL in older adults with cognitive impairment. Specifically, balance has significant indirect effects on the physical comp...

Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.

Both Alzheimer's disease (AD) genetic risk factors and indices of cognitive reserve (CR) influence risk of cognitive decline, but it remains unclear whether they interact. This study examined whether ... Analyses used data from the Preclinical AD Consortium, including harmonized data from 5 longitudinal cohort studies. Participants were cognitively normal at baseline (M baseline age = 64 years, 59% fe... In mixed-effects models, higher CR index scores were associated with better baseline cognitive performance for all cognitive outcomes. APOE-ε4 genotype and AD-PRS that included the APOE region (AD-PRS... These results suggest that APOE-ε4 and non-APOE-ε4 AD polygenic risk are independently associated with global cognitive and executive function declines among individuals with normal cognition at basel...

The use of subjective cognitive complaints for detecting mild cognitive impairment in older adults across cultural and linguistic groups: A comparison of the Cognitive Function Instrument to the Montreal Cognitive Assessment.

This pilot study aims to explore the psychometric properties of the Cognitive Function Instrument (CFI) as a measure of subjective cognitive complaints (SCC) and its performance in distinguishing mild... One hundred ninety-four community-dwelling non-demented older adults with racial/ethnic diversity were included. Unidimensionality and internal consistency of the CFI were examined using factor analys... The CFI demonstrated adequate internal consistency; however, the fit for a unidimensional model was suboptimal. The CFI distinguished MCI from NC alone or in combination with MoCA. ROC analysis showed... Our findings support the use of CFI as a brief and easy-to-use screen to detect MCI in culturally/linguistically diverse older adults.... What is the key scientific question or problem of central interest of the paper? Subjective cognitive complaints (SCCs) are considered the earliest sign of dementia in older adults. However, it is unc...